Combination of Local Ablative Techniques with Radiotherapy for Primary and Recurrent Lung Cancer: A Systematic Review.

RT SBRT combining LTA-RT lung cancer percutaneous image-guided local tumor ablation (LTA)

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
16 Dec 2023
Historique:
received: 28 09 2023
revised: 04 12 2023
accepted: 07 12 2023
medline: 23 12 2023
pubmed: 23 12 2023
entrez: 23 12 2023
Statut: epublish

Résumé

In patients with early-stage or recurrent NSCLC who are unable to tolerate surgery, a benefit could derive only from a systemic therapy or another few forms of local therapy. A systematic review was performed to evaluate the feasibility and the effectiveness of radiotherapy combined with local ablative therapies in the treatment of primary and recurrent lung cancer in terms of toxicity profile and local control rate. Six studies featuring a total of 115 patients who met eligibility criteria and 119 lesions were included. Three studies evaluated lung cancer patients with a medically inoperable condition treated with image-guided local ablative therapies followed by radiotherapy: their local control rate (LC) ranged from 75% to 91.7% with only 15 patients (19.4%) reporting local recurrence after combined modality treatment. The other three studies provided a salvage option for patients with locally recurrent NSCLC after RT: the median follow-up period varied from 8.3 to 69.3 months with an LC rate ranging from 50% to 100%. The most common complications were radiation pneumonitis (9.5%) and pneumothorax (29.8%). The proposed intervention appears to be promising in terms of toxicity profile and local control rate. Further prospective studies are need to better delineate combining LTA-RT treatment benefits in this setting.

Identifiants

pubmed: 38136413
pii: cancers15245869
doi: 10.3390/cancers15245869
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Auteurs

Paolo Bonome (P)

Radiation Oncology Unit, Responsible Research Hospital, 86100 Campobasso, Italy.

Donato Pezzulla (D)

Radiation Oncology Unit, Responsible Research Hospital, 86100 Campobasso, Italy.

Valentina Lancellotta (V)

Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, UOC Radioterapia Oncologica, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, 00168 Rome, Italy.

Anna Rita Scrofani (AR)

Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, UOC Radiologia d'Urgenza ed Interventistica, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, 00168 Rome, Italy.

Gabriella Macchia (G)

Radiation Oncology Unit, Responsible Research Hospital, 86100 Campobasso, Italy.

Elena Rodolfino (E)

Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, UOC Radiologia Addomino-Pelvica, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, 00168 Rome, Italy.

Luca Tagliaferri (L)

Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, UOC Radioterapia Oncologica, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, 00168 Rome, Italy.

György Kovács (G)

Gemelli-INTERACTS, Università Cattolica del Sacro Cuore, 20123 Rome, Italy.

Francesco Deodato (F)

Radiation Oncology Unit, Responsible Research Hospital, 86100 Campobasso, Italy.
Radiology Institute, Università Cattolica del Sacro Cuore, 00135 Rome, Italy.

Roberto Iezzi (R)

Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, UOC Radiologia d'Urgenza ed Interventistica, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, 00168 Rome, Italy.

Classifications MeSH